{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:46:03Z","timestamp":1793807163855,"version":"4.6.1"},"reference-count":140,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007172","name":"Cincinnati Children's Hospital Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08-AR072075"],"award-info":[{"award-number":["K08-AR072075"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014452","name":"College of Medicine, University of Cincinnati","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.rdc.2021.06.003","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T07:15:35Z","timestamp":1629530135000},"page":"585-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis"],"prefix":"10.1016","volume":"47","author":[{"given":"Remco","family":"Erkens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ysabella","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Towe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Schulert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Vastert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.rdc.2021.06.003_bib1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","article-title":"Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions","volume":"7","author":"Mellins","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.06.003_bib2","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa118","article-title":"Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience","author":"Chhabra","year":"2020","journal-title":"Reumatology (Oxford)"},{"key":"10.1016\/j.rdc.2021.06.003_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/acr.23853","article-title":"Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis cohort","author":"Glerup","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2021.06.003_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/art.41390","article-title":"New medications are needed for children with juvenile idiopathic arthritis","author":"Brunner","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-020-00444-7","article-title":"Proceedings from the 2ndNext Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019","author":"Canna","year":"2020","journal-title":"Pediatr Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2021.06.003_bib7","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2021.06.003_bib8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2021.06.003_bib9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2019-215051","article-title":"Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis","volume":"78","author":"Gohar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.06.003_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/pr.2013.187","article-title":"Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis","author":"Correll","year":"2014","journal-title":"Pediatr Res"},{"key":"10.1016\/j.rdc.2021.06.003_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis","author":"Dewitt","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2021.06.003_bib12","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1521837113","article-title":"Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis","author":"Nigrovic","year":"2015","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.rdc.2021.06.003_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8464","article-title":"IL-1 receptor antagonist-deficient mice develop autoimmune arthritis due to intrinsic activation of IL-17-producing CCR2\u00a0+ V\u03b36\u00a0+ \u03b3\u03b4T cells","author":"Akitsu","year":"2015","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.rdc.2021.06.003_bib14","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/art.40099","article-title":"Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by gamma\/delta T Cells in Systemic Juvenile Idiopathic Arthritis","volume":"69","author":"Kessel","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132508","article-title":"Th17 reprogramming of T\u00a0cells in systemic juvenile idiopathic arthritis","author":"Henderson","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.rdc.2021.06.003_bib16","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis","author":"Lovell","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.rdc.2021.06.003_bib17","first-page":"935","article-title":"Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis","volume":"32","author":"Kimura","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/art.21885","article-title":"Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis","author":"Lovell","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.06.003_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s12519-015-0009-3","article-title":"Effect of etanercept on refractory systemic-onset juvenile idiopathic arthritis","author":"Hu","year":"2016","journal-title":"World J Pediatr"},{"key":"10.1016\/j.rdc.2021.06.003_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1462-2","article-title":"Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry","author":"Horneff","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.rdc.2021.06.003_bib21","first-page":"545","article-title":"Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept","volume":"23","author":"Katsicas","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib22","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.090952","article-title":"Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents","author":"Russo","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rdc.2021.06.003_bib24","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2021.06.003_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3899\/jrheum.100726","article-title":"Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series","volume":"38","author":"Record","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.06.003_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.rdc.2021.06.003_bib28","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis","author":"Huang","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.rdc.2021.06.003_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216699","article-title":"Tofacitinib in refractory adult-onset Still\u2019s disease: 14 cases from a single centre in China","author":"Hu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.06.003_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001246","article-title":"Mixed results with baricitinib in biological-resistant adult-onset Still\u2019s disease and undifferentiated systemic autoinflammatory disease","author":"Kacar","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.rdc.2021.06.003_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key414","article-title":"Treatment of refractory adult onset Still\u2019s disease with combination anakinra and baricitinib therapy","author":"Ladhari","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.rdc.2021.06.003_bib32","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","article-title":"Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.06.003_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.06.003_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.06.003_bib36","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1205099","article-title":"Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis","author":"Ruperto","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2021.06.003_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab047","article-title":"Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis","author":"Ruperto","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2021.06.003_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kep122","article-title":"Safety and efficacy of once weekly etanercept 0.8\u00a0mg\/kg in a multicentre 12\u00a0week trial in active polyarticular course juvenile idiopathic arthritis","author":"Horneff","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2021.06.003_bib39","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.141261","article-title":"Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","author":"Minoia","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib40","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-010-1413-6","article-title":"Intravenous immunoglobulin therapy leading to dramatic improvement in a patient with systemic juvenile idiopathic arthritis and severe pericarditis resistant to steroid pulse therapy","author":"Aizawa-Yashiro","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.rdc.2021.06.003_bib41","article-title":"Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report","author":"Bader-Meunier","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.06.003_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients","author":"Kim","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rdc.2021.06.003_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/JCI129301","article-title":"Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases","author":"de Jesus","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.rdc.2021.06.003_bib44","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","author":"Montealegre Sanchez","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.rdc.2021.06.003_bib45","first-page":"259","article-title":"Sequential changes to clinical parameters and adhesion molecules following intravenous pulse cyclophosphamide and methylprednisolone treatment of refractory juvenile idiopathic arthritis","volume":"22","author":"Chen","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib46","article-title":"Side effects of medications used to treat childhood interstitial lung disease","author":"Breuer","year":"2018","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.rdc.2021.06.003_bib47","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.130133","article-title":"High doses of infliximab in the management of juvenile idiopathic arthritis","author":"Tambralli","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.3169","article-title":"OP0290 Emapalumab (anti-interferon-gamma monoclonal antibody) in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (SJIA)","author":"De Benedetti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.06.003_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez350","article-title":"Anakinra in children and adults with Still\u2019s disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2021.06.003_bib50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib51","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-med-061813-012806","article-title":"Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies","author":"Schulert","year":"2015","journal-title":"Annu Rev Med"},{"issue":"3","key":"10.1016\/j.rdc.2021.06.003_bib52","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborat","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib54","doi-asserted-by":"crossref","DOI":"10.1007\/s12519-019-00256-0","article-title":"Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China","author":"Zou","year":"2020","journal-title":"World J Pediatr"},{"key":"10.1016\/j.rdc.2021.06.003_bib55","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-016-3545-9","article-title":"Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus","author":"Ayta\u00e7","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.rdc.2021.06.003_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiv550","article-title":"Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza","author":"Schulert","year":"2016","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.rdc.2021.06.003_bib57","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/art.22416","article-title":"The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis","volume":"56","author":"Bleesing","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2021.06.003_bib58","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","author":"Saper","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.06.003_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/art.41073","article-title":"systemic juvenile idiopathic arthritis\u2013associated lung disease: characterization and risk factors","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/acr.23277","article-title":"Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2021.06.003_bib62","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-020-0399-1","article-title":"Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","author":"Shimizu","year":"2020","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib63","article-title":"Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis","author":"Lee","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.06.003_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11048","article-title":"Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic Arthritis","author":"Eloseily","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2018.05.017","article-title":"Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis","author":"Sakumura","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.rdc.2021.06.003_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108252","article-title":"Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","author":"Takakura","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.rdc.2021.06.003_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/s41390-020-0843-4","article-title":"Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy","author":"Irabu","year":"2020","journal-title":"Pediatr Res"},{"key":"10.1016\/j.rdc.2021.06.003_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2021.02.008","article-title":"Sudden Hypotension and Increased Serum IFN-\u03b3 and IL-10 Predict Early Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients","author":"Guo","year":"2021","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.rdc.2021.06.003_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.rdc.2021.06.003_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","author":"Ravelli","year":"2012","journal-title":"Genes Immun"},{"issue":"3","key":"10.1016\/j.rdc.2021.06.003_bib71","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1067\/mpd.2003.110","article-title":"Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"142","author":"Grom","year":"2003","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1016\/j.rdc.2021.06.003_bib72","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/rheumatology\/kep418","article-title":"Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis","volume":"49","author":"Vastert","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2021.06.003_bib73","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar1453","article-title":"Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome","volume":"7","author":"Villanueva","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2021.06.003_bib74","doi-asserted-by":"crossref","DOI":"10.1007\/s40272-019-00367-1","article-title":"Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management","author":"Henderson","year":"2020","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.rdc.2021.06.003_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/s41435-020-0098-4","article-title":"The genetics of macrophage activation syndrome","author":"Schulert","year":"2020","journal-title":"Genes Immun"},{"key":"10.1016\/j.rdc.2021.06.003_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101515","article-title":"Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy","author":"Griffin","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib77","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation-2009.1.127","article-title":"Hemophagocytic lymphohistiocytosis (HLH) and related disorders","author":"Filipovich","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rdc.2021.06.003_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/art.38793","article-title":"Whole-Exome Sequencing Reveals Overlap Between Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Familial Hemophagocytic Lymphohistiocytosis","author":"Kaufman","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib79","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-014-0439-2","article-title":"Genetic Defects in Cytolysis in Macrophage Activation Syndrome","author":"Zhang","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"10.1016\/j.rdc.2021.06.003_bib80","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/art.23734","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms","volume":"58","author":"Zhang","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.06.003_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/art.23199","article-title":"Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis","author":"Hazen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.06.003_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.03089","article-title":"Natural killer cells in systemic autoinflammatory diseases: a focus on systemic juvenile idiopathic arthritis and macrophage activation syndrome","author":"Vandenhaute","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.rdc.2021.06.003_bib83","doi-asserted-by":"crossref","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome: like disease in mice","author":"Behrens","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.rdc.2021.06.003_bib84","doi-asserted-by":"crossref","DOI":"10.2741\/3982","article-title":"Understanding TLR9 action in Epstein Barr virus infection","author":"Zauner","year":"2012","journal-title":"Front Biosci"},{"key":"10.1016\/j.rdc.2021.06.003_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/art.22981","article-title":"Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome","author":"Fall","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2021.06.003_bib86","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.06.003_bib87","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keu524","article-title":"Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-\u03b3","author":"Put","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2021.06.003_bib88","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8\u00a0+ T\u00a0cells and interferon gamma are essential for the disorder","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2021.06.003_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2011.11.046","article-title":"Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children","author":"Xu","year":"2012","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.rdc.2021.06.003_bib90","article-title":"IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome","author":"Yasin","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2021.06.003_bib91","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/ard.2006.061853","article-title":"Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study","volume":"66","author":"de Jager","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.06.003_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.rdc.2021.06.003_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2014.05.002","article-title":"Update on research and clinical translation on specific clinical areas: from bench to bedside: how insight in immune pathogenesis can lead to precision medicine of severe juvenile idiopathic arthritis","volume":"28","author":"Vastert","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"13","key":"10.1016\/j.rdc.2021.06.003_bib94","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2021.06.003_bib95","doi-asserted-by":"crossref","DOI":"10.1111\/ped.13679","article-title":"Transient natural killer cell dysfunction associated with interleukin-18 overproduction in systemic juvenile idiopathic arthritis","author":"Takakura","year":"2018","journal-title":"Pediatr Int"},{"issue":"9","key":"10.1016\/j.rdc.2021.06.003_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/art.24750","article-title":"Defective phosphorylation of interleukin-18 receptor \u03b2 causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis","volume":"60","author":"De Jager","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2021.06.003_bib97","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.rdc.2021.06.003_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.rdc.2021.06.003_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.hoc.2015.06.010","article-title":"Macrophage Activation Syndrome","author":"Ravelli","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.rdc.2021.06.003_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2020.12.007","article-title":"Understanding of cytokines and targeted therapy in macrophage activation syndrome","author":"Tang","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.06.003_bib101","doi-asserted-by":"crossref","DOI":"10.1002\/art.39407","article-title":"Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Canakinumab","author":"Grom","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib102","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.140288","article-title":"Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab","author":"Yokota","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"25","key":"10.1016\/j.rdc.2021.06.003_bib103","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2021.06.003_bib104","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-018-4095-1","article-title":"Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature","author":"S\u00f6nmez","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib105","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","author":"Miettunen","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2021.06.003_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/art.41103","article-title":"Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis","author":"Eloseily","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib107","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","author":"Locatelli","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2021.06.003_bib108","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","author":"Vallurupalli","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2021.06.003_bib109","doi-asserted-by":"crossref","DOI":"10.21037\/atm-20-3127","article-title":"Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still\u2019s disease: case report and review of the literature","author":"Gabr","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.rdc.2021.06.003_bib110","article-title":"Emapalumab: first global approval","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.rdc.2021.06.003_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","author":"Canna","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.rdc.2021.06.003_bib112","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kez284","article-title":"IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2021.06.003_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.rdc.2021.06.003_bib114","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib115","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-018-0792-7","article-title":"JAK inhibitors in rheumatology: implications for paediatric syndromes?","author":"Kerrigan","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2021.06.003_bib116","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","author":"Das","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2021.06.003_bib117","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-02-700013","article-title":"Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice","author":"Maschalidi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2021.06.003_bib118","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020006075","article-title":"JAK\/STAT pathway inhibition sensitizes CD8 T\u00a0cells to dexamethasone-induced apoptosis in hyperinflammation","author":"Meyer","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2021.06.003_bib119","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201903-0659OC","article-title":"Synergistic signaling of TLR and IFN\u03b1\/\u03b2 facilitates escape of IL-18 expression from endotoxin tolerance","author":"Verweyen","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2021.06.003_bib120","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17331","article-title":"Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial","author":"Wang","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rdc.2021.06.003_bib121","doi-asserted-by":"crossref","DOI":"10.1080\/03009742.2020.1729405","article-title":"Tofacitinib-induced remission in refractory adult-onset Still\u2019s disease complicated by macrophage activation syndrome","author":"Honda","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.pcl.2018.04.005","article-title":"Systemic juvenile idiopathic arthritis","author":"Lee","year":"2018","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.rdc.2021.06.003_bib123","doi-asserted-by":"crossref","DOI":"10.1002\/acr.21889","article-title":"Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis","author":"Kimura","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2021.06.003_bib124","article-title":"IL-1 and IL-6 inhibitor hypersensitivity link to common HLA-DRB1\u221715 alleles","author":"Hollenbach","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.rdc.2021.06.003_bib125","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201305-0923ST","article-title":"An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy","author":"Kurland","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2021.06.003_bib126","article-title":"Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease","author":"Sato","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2021.06.003_bib127","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.200941","article-title":"Efficacy of moderately dosed etoposide in macrophage activation syndrome - hemophagocytic lymphohistiocytosis (MAS-HLH)","author":"Horne","year":"2021","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2021.06.003_bib128","doi-asserted-by":"crossref","DOI":"10.1097\/ACI.0000000000000730","article-title":"Safety of anti-inflammatory drugs in children with asthma","author":"de Benedictis","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.rdc.2021.06.003_bib129","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.12942","article-title":"Azithromycin and the treatment of lymphocytic airway inflammation after lung transplantation","author":"Vos","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.rdc.2021.06.003_bib130","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1913590","article-title":"Inhaled molgramostim therapy in autoimmune pulmonary alveolar proteinosis","author":"Trapnell","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2021.06.003_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2018.10.018","article-title":"Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs","author":"Schmajuk","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.06.003_bib132","doi-asserted-by":"crossref","DOI":"10.1111\/jeu.12631","article-title":"The 14th International Workshops on Opportunistic Protists (IWOP 14)","author":"Cushion","year":"2018","journal-title":"J\u00a0Eukaryot Microbiol"},{"key":"10.1016\/j.rdc.2021.06.003_bib133","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201812-2276ST","article-title":"Home oxygen therapy for children an official American Thoracic Society clinical practice guideline","author":"Hayes","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rdc.2021.06.003_bib134","doi-asserted-by":"crossref","DOI":"10.4187\/respcare.06697","article-title":"Cystic fibrosis lung disease: an overview","author":"Turcios","year":"2020","journal-title":"Respir Care"},{"key":"10.1016\/j.rdc.2021.06.003_bib135","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02990-2020","article-title":"Task force report: European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis","author":"Chang","year":"2021","journal-title":"Eur Respir J"},{"issue":"26","key":"10.1016\/j.rdc.2021.06.003_bib136","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1056\/NEJMra023226","article-title":"Pulmonary alveolar proteinosis","volume":"349","author":"Trapnell","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2021.06.003_bib137","series-title":"Diagnostic and interventional bronchoscopy in children","first-page":"443","article-title":"Whole-Lung Lavage","author":"Towe","year":"2021"},{"issue":"7","key":"10.1016\/j.rdc.2021.06.003_bib138","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.22656","article-title":"Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial","volume":"56","author":"Brinkman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.06.003_bib139","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez157","article-title":"Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients","author":"Swart","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.rdc.2021.06.003_bib140","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/bloodadvances.2017014449","article-title":"Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis","volume":"2","author":"M F Silva","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.rdc.2021.06.003_bib141","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1136\/ard.2003.017798","article-title":"Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity","volume":"63","author":"De Kleer","year":"2004","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X21010929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X21010929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:20:04Z","timestamp":1760181604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X21010929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":140,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0889857X21010929"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2021.06.003","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2021.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}